================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): August 26, 2004
Medicis Pharmaceutical Corporation
(Exact Name of Registrant as Specified in Its Charter)
Delaware 0-18443 52-1574808
(State or Other Jurisdiction of (Commission File Number) (IRS Employer
Incorporation) Identification No.)
8125 North Hayden Road
Scottsdale, Arizona 85258-2463
(Address of Principal (Zip Code)
Executive Offices)
Registrant's telephone number, including area code: (602) 808-8800
N/A
------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
Item 8.01. Other Events
On August 26, 2004, Medicis Pharmaceutical Corporation ("Medicis")
entered into a pre-arranged stock trading plan to purchase up to $150,000,000 in
aggregate value of shares of Medicis' Class A common stock upon satisfaction of
certain conditions. Medicis' plan was adopted in accordance with guidelines
specified under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
The plan is scheduled to terminate on the earlier of the first anniversary of
the plan or at the time when the purchase limit is reached.
Rule 10b5-1 permits insiders who are not in possession of material,
non-public information to establish pre-arranged plans to buy or sell company
stock in order to avoid concerns about initiating stock transactions while in
possession of material nonpublic information.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.
MEDICIS PHARMACEUTICAL CORPORATION
(Registrant)
Date: August 30, 2004 /s/ Mark A. Prygocki, Sr.
------------------------------------------
Name: Mark A. Prygocki, Sr.
Title: Executive Vice President, Chief
Financial Officer, Corporate
Secretary and Treasurer